cti Logo
Site Map Contact Terms of Use Privacy
Search
Making Cancer More Treatable
About CTI cancer treatment drugs CTI Products for Cancer Treatment and Clinical Trials Investors Media Career
About CTI Cancer Treatment Drugs and Drug Pipeline CTI Products for cancer treatment and clinical trials Investors Media Career  

spacer
  News about CTI's cancer research and clinical trials
 

ZEVALIN

Clinical trials for XYOTAX, pixantrone, CT-2106

Aequus Biopharma

Sito italiano

 

 


sp

 

May 15 - CTI to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference

May 8 - Zevalin Revenues Lead CTI's First Quarter 2008 Financial Results

May 5 - European Regulatory Agency Supports OPAXIO(TM) Brand Name for Cell Therapeutics' Lung Cancer Drug

April 30 - CTI Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor

April 24 - Veteran Drug Industry Executive to Become President of CTI

More Press Releases

     
      Copyright © 2004-2007 Cell Therapeutics, Inc., Seattle, WA, USA. All rights reserved.
"Making cancer more treatable" is a registered mark of CTI. All rights reserved. Terms of Use